The Cancer Institute of New Jersey, New Brunswick, is offering more than 130 clinical trials.
Most cancer clinical trials are medical studies that test new treatments and new ways of using existing treatments for cancer. Researchers use these clinical trials to answer questions about a treatment and to make sure it is safe and effective.
There are several types of clinical trials, including treatment, prevention, screening and behavioral.
Treatment trials use a drug with the intention of curing, prolonging or improving the life of patients with cancer. Prevention trials test ways of preventing cancer from developing or returning, and screening trials study ways to detect cancer in early stages, making treatment more effective. Behavioral trials study quality of life, methods to improve enrollment to clinical trials, and reasons why patients choose different treatment options.
Across these categories, CINJ offers clinical trials for breast, prostate, lung, colon, ovarian, bladder, renal, skin, and pediatric cancers, among others.
According to a press release from the Cancer Institute of New Jersey, CINJ currently enrolls more than 1,000 patients in clinical trials, or approximately 15 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients on clinical trials. Enrollment in clinical trials nationwide is only 2-4 percent of all adult cancer patients.
Several CINJ clinical treatment trials are available at hospitals and doctor’s offices through the CINJ Oncology Group, a network of hospitals and doctors who are Partners and Affiliates of CINJ.
For more information, call (732) 235-CINJ or (866) 654-9898. Information on cancer clinical trials offered at CINJ and throughout the state can also be found on the Web at New Jersey Cancer Trial Connect, www.njctc.org.
The Cancer Institute of New Jersey is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. CINJ is part of UMDNJ-Robert Wood Johnson Medical School.